title: HMGB1 in renal ischemic injury.
abstract: Factors that initiate cellular damage and trigger the inflammatory response cascade and renal injury are not completely understood after renal ischemia-reperfusion injury (IRI). High-mobility group box-1 protein (HMGB1) is a damage-associated molecular pattern molecule that binds to chromatin, but upon signaling undergoes nuclear-cytoplasmic translocation and release from cells. Immunohistochemical and Western blot analysis identified HMGB1 nuclear-cytoplasmic translocation and release from renal cells (particularly vascular and tubular cells) into the venous circulation after IRI. Time course analysis indicated HMGB1 release into the venous circulation progressively increased parallel to increased renal ischemic duration. Ethyl pyruvate (EP) treatment blocked H(2)O(2) (oxidative stress)-induced HMGB1 release from human umbilical vein endothelial cells in vitro, and in vivo resulted in nuclear retention and significant blunting of HMGB1 release into the circulation after IRI. EP treatment before IRI improved short-term serum creatinine and albuminuria, proinflammatory cyto-/chemokine release, and long-term albuminuria and fibrosis. The renoprotective effect of EP was abolished when exogenous HMGB1 was injected, suggesting EP's therapeutic efficacy is mediated by blocking HMGB1 translocation and release. To determine the independent effects of circulating HMGB1 after injury, exogenous HMGB1 was administered to healthy animals at pathophysiological dose. HMGB1 administration induced a rapid surge in systemic circulating cyto-/chemokines (including TNF-α, eotaxin, G-CSF, IFN-γ, IL-10, IL-1α, IL-6, IP-10, and KC) and led to mobilization of bone marrow CD34+Flk1+ cells into the circulation. Our results indicate that increased ischemic duration causes progressively enhanced HMGB1 release into the circulation triggering damage/repair signaling, an effect inhibited by EP because of its ability to block HMGB1 nuclear-cytoplasmic translocation.
authors: Departments of Medicine, Pharmacology, and Physiology, New York Medical College, Valhalla, 10595, USA.
authors: May M
authors: MM
authors: Rabadi
authors: Tammer
authors: T
authors: Ghaly
authors: Michael S
authors: MS
authors: Goligorksy
authors: Brian B
authors: BB
authors: Ratliff
mesh_terms: D000818:Animals; D001854:Bone Marrow Cells / Q000502:physiology; D003404:Creatinine / Q000097:blood; D016207:Cytokines / Q000097:blood; D006609:High Mobility Group Proteins / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D006861:Hydrogen Peroxide / Q000378:metabolism; D007668:Kidney / Q000098:blood supply*; D008297:Male; D051379:Mice; D018384:Oxidative Stress / Q000187:drug effects; D011773:Pyruvates / Q000494:pharmacology; D015427:Reperfusion Injury / Q000378:metabolism*; D012097:Repressor Proteins / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology
chemical_list: D016207:Cytokines; C486328:HBP1 protein, human; C486329:Hbp1 protein, mouse; D006609:High Mobility Group Proteins; D011773:Pyruvates; D012097:Repressor Proteins; C046522:ethyl pyruvate; D003404:Creatinine; D006861:Hydrogen Peroxide